Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

Share Price is delayed by 15 minutes
Get Live Data
630.00    30.00 (5.00%)
Bid:
626.00
Ask:
634.00
Spread: 8.00 (1.278%)
Market Cap: £762.36m
OXB Live PriceLast checked at - London Stock Exchange

Intraday Oxford Biomedica Share Chart

Director Declaration

2 Jul 2025 07:00

RNS Number : 3814P
Oxford Biomedica PLC
02 July 2025
 

 

 

 

OXB Directorship notification under UK Listing Rule 6.4.9R(2)

Oxford, UK - 2 July 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Mr. Colin Bond, Independent Non-Executive Director, has been appointed as Additional Director (Non-Executive, Independent) of OneSource Specialty Pharma Limited, a company listed at the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange Limited (BSE), subject to the approval of the shareholders by way of special resolution expected to be announced on or around 1 August 2025.

 

-Ends-

 

Enquiries:

 

OXB

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

 

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNRTMATMTIMMRA
Date   Source Headline
2nd Jun 20267:00 amRNSOXB Capital Markets Event
1st Jun 20267:00 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirector Declaration
22nd May 20262:17 pmRNSDirector/PDMR Shareholding
19th May 20269:56 amRNSPDMR Dealing
13th May 202610:52 amRNSPDMR Dealing
7th May 20264:58 pmRNSResult of AGM
1st May 20267:00 amRNSTotal Voting Rights
30th Apr 20268:15 amRNSAdmission to Trading
27th Apr 20269:51 amRNSAdmission to Trading Application
13th Apr 20267:00 amRNS-RLaunch of viral vector fast-track offering
8th Apr 20265:18 pmRNSGrant of Awards
1st Apr 20267:00 amRNSTotal Voting Rights
30th Mar 20263:30 pmRNS2026 Annual General Meeting notification
26th Mar 20267:00 amRNSPreliminary results for the year ended 31 Dec 2025
18th Mar 20267:00 amRNS-RLicensing agreement with VVMF
9th Mar 20267:53 amRNSAdmission to Trading
4th Mar 202611:45 amRNSAdmission to Trading Application
3rd Mar 20267:00 amRNSCapital Markets Day and investor conferences
2nd Mar 20267:00 amRNSTotal Voting Rights
27th Feb 20261:31 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
26th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
26th Feb 20261:49 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
26th Feb 202612:33 pmRNSForm 8.3 - Oxford Biomedica plc
26th Feb 202611:09 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
26th Feb 202611:08 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
26th Feb 20269:42 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica plc
25th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
25th Feb 20262:32 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
25th Feb 202612:33 pmRNSResponse to Rule 2.8 Announcement
25th Feb 202612:12 pmRNSDisclosure Table
25th Feb 202612:00 pmRNSRule 2.8 Announcement
25th Feb 202611:46 amRNSForm 8.3 - Oxford Biomedica plc
25th Feb 202610:53 amRNSForm 8.5 (EPT/NON-RI) Oxford Biomedica Plc
25th Feb 202610:17 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
25th Feb 202610:15 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
24th Feb 20267:29 amRNSForm 8.5 (EPT/RI)-Oxford Biomedica plc
24th Feb 20267:25 amRNSForm 8.5 (EPT/NON-RI)-Oxford Biomedica plc
24th Feb 20267:03 amRNSFull year Trading Update and Notice of Results
23rd Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
23rd Feb 20262:20 pmEQSForm 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
23rd Feb 20267:40 amRNSForm 8.5 (EPT/RI)-Oxford Biomedica plc
23rd Feb 20267:39 amRNSForm 8.5 (EPT/NON-RI)-Oxford Biomedica plc
20th Feb 20263:20 pmRNSForm 8.3 - Oxford Biomedica plc
20th Feb 20261:46 pmRNSForm 8.3 - Oxford Biomedica Plc
20th Feb 20268:13 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc
20th Feb 20268:08 amRNSForm 8.5 (EPT/NON-RI) - Oxford Biomedica plc
19th Feb 20262:39 pmRNSForm 8.5 (EPT/RI)-Replacement of Oxford Biomedica
19th Feb 20269:44 amRNSRule 2.9 Announcement
19th Feb 20268:04 amRNSForm 8.5 (EPT/RI) - Oxford Biomedica plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.